着床前診断(PGD)のグローバル市場(2020~2030):染色体異常、異数性、X連鎖疾患、単一遺伝子疾患、その他

■ 英語タイトル:Preimplantation Genetics Diagnosis (PGD) Market By Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

調査会社Allied Market Research社が発行したリサーチレポート(データ管理コード:ALD22AU238)■ 発行会社/調査会社:Allied Market Research
■ 商品コード:ALD22AU238
■ 発行日:2022年3月
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:160
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single UserUSD5,769 ⇒換算¥853,812見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥954,600見積依頼/購入/質問フォーム
Enterprise UserUSD10,995 ⇒換算¥1,627,260見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[着床前診断(PGD)のグローバル市場(2020~2030):染色体異常、異数性、X連鎖疾患、単一遺伝子疾患、その他]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Allied Market Research社は、2020年に81.52百万ドルであった世界の着床前診断(PGD)市場が、2021年から2030年まで年平均10.3%成長し、2030年までに217.18百万ドルに達すると予測しています。当書では、着床前診断(PGD)の世界市場を対象に総合的に調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、検査種類別(染色体異常、異数性、X連鎖疾患、単一遺伝子疾患、その他)分析、地域別分析、企業状況、企業情報などの項目をまとめております。なお、当書に掲載されている企業情報には、Agilent Technologies, Inc.、cegat gmbh、Illumina Inc.、Invitae Corporation、Laboratory Corporation of America Holdings、Natera Inc.、pacgenomics、PerkinElmer, Inc.、Quest Diagnostics Inc.、Reproductive Genetic Innovations (RGI)などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の着床前診断(PGD)市場規模:検査種類別(染色体異常、異数性、X連鎖疾患、単一遺伝子疾患、その他)
・世界の着床前診断(PGD)市場規模:地域別
・企業状況
・企業情報

The global preimplantation genetic diagnosis (PGD) market size was valued at $81.52 million in 2020, and is projected to reach $217.18 million by 2030, registering a CAGR of 10.3% from 2021 to 2030. Preimplantation genetic diagnosis (PGD) is called as embryo screening. It is a branch of genetics that involves genetic testing of embryos through in vitro fertilization (IVF).
PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders, including  spinal muscular atrophy and cystic fibrosis.
PGD provides effective solution for healthy embryos free from genetic, hereditary, and chromosomal disorders. It is an evolving technique in modern genetic study.  In addition, increase in prevalence of hereditary, chromosomal, and genetic disorders every year that include triploidy, thalassemia, and Duchenne muscular dystrophy (DMD)requires PGD for the diagnosis of mutational changes. Moreover, increase in usage of PGD techniques in selecting human leukocyte antigen (HLA) profile to match existing sibling with disease and sex balancing in family spurred the growth of PGD market. Furthermore, growth in infertility rate and increase in awareness regarding PGD technique boost the growth of the market.

The global PGD market is segmented on the basis of test type and region. By test type, the market is classified into chromosomal abnormalities, aneuploidy, X-linked diseases, single gene disorders, HLA typing, gender selection, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market.

COMPETITION ANALYSIS
The major market participants profiled in this report include Agilent Technologies, Inc., CeGaT GmbH, Illumina Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Natera Inc., PacGenomics, PerkinElmer, Inc., Quest Diagnostics Inc., and Reproductive Genetic Innovations (RGI)

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the preimplantation genetics diagnosis market analysis from 2020 to 2030 to identify the prevailing preimplantation genetics diagnosis market opportunity.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the preimplantation genetics diagnosis (pgd) market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●The key players within preimplantation genetics diagnosis industry are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the preimplantation genetics diagnosis industry.
●The report includes the analysis of the regional as well as global preimplantation genetics diagnosis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Test Type
● Chromosomal Abnormalities
● Aneuploidy
● X-linked diseases
● Single Gene Disorders
● HLA Typing
● Gender selection
● Others

By Region
● Asia-Pacific
○ China
○ Japan
○ India
○ South Korea
○ Rest Of Asia Pacific
● LAMEA
○ Latin America
○ Middle East
○ Africa
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ U.K.
○ Italy
○ Rest of Europe

● Key Market Players
○ Agilent Technologies, Inc.
○ cegat gmbh
○ Illumina Inc.
○ Invitae Corporation
○ Laboratory Corporation of America Holdings
○ Natera Inc.
○ pacgenomics
○ PerkinElmer, Inc.
○ Quest Diagnostics Inc.
○ Reproductive Genetic Innovations (RGI)

*** レポート目次(コンテンツ)***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Chromosomal Abnormalities
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Aneuploidy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 X-linked diseases
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Single Gene Disorders
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 HLA Typing
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Gender selection
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
4.8 Others
4.8.1 Key market trends, growth factors and opportunities
4.8.2 Market size and forecast, by region
4.8.3 Market analysis by country
CHAPTER 5: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 Asia-Pacific
5.2.1 Key trends and opportunities
5.2.2 Asia-Pacific Market size and forecast, by Test Type
5.2.3 Asia-Pacific Market size and forecast, by country
5.2.3.1 China
5.2.3.1.1 Market size and forecast, by Test Type
5.2.3.2 Japan
5.2.3.2.1 Market size and forecast, by Test Type
5.2.3.3 India
5.2.3.3.1 Market size and forecast, by Test Type
5.2.3.4 South Korea
5.2.3.4.1 Market size and forecast, by Test Type
5.2.3.5 Rest Of Asia Pacific
5.2.3.5.1 Market size and forecast, by Test Type
5.3 LAMEA
5.3.1 Key trends and opportunities
5.3.2 LAMEA Market size and forecast, by Test Type
5.3.3 LAMEA Market size and forecast, by country
5.3.3.1 Latin America
5.3.3.1.1 Market size and forecast, by Test Type
5.3.3.2 Middle East
5.3.3.2.1 Market size and forecast, by Test Type
5.3.3.3 Africa
5.3.3.3.1 Market size and forecast, by Test Type
5.4 North America
5.4.1 Key trends and opportunities
5.4.2 North America Market size and forecast, by Test Type
5.4.3 North America Market size and forecast, by country
5.4.3.1 U.S.
5.4.3.1.1 Market size and forecast, by Test Type
5.4.3.2 Canada
5.4.3.2.1 Market size and forecast, by Test Type
5.4.3.3 Mexico
5.4.3.3.1 Market size and forecast, by Test Type
5.5 Europe
5.5.1 Key trends and opportunities
5.5.2 Europe Market size and forecast, by Test Type
5.5.3 Europe Market size and forecast, by country
5.5.3.1 Germany
5.5.3.1.1 Market size and forecast, by Test Type
5.5.3.2 France
5.5.3.2.1 Market size and forecast, by Test Type
5.5.3.3 U.K.
5.5.3.3.1 Market size and forecast, by Test Type
5.5.3.4 Italy
5.5.3.4.1 Market size and forecast, by Test Type
5.5.3.5 Rest of Europe
5.5.3.5.1 Market size and forecast, by Test Type
CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments
CHAPTER 7: COMPANY PROFILES
7.1 Agilent Technologies, Inc.
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 cegat gmbh
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 Illumina Inc.
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 Invitae Corporation
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 Laboratory Corporation of America Holdings
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 Natera Inc.
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 pacgenomics
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 PerkinElmer, Inc.
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 Quest Diagnostics Inc.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 Reproductive Genetic Innovations (RGI)
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 2. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR CHROMOSOMAL ABNORMALITIES, BY REGION , 2020-2030,($THOUSAND)
TABLE 3. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET CHROMOSOMAL ABNORMALITIES BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 4. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR ANEUPLOIDY, BY REGION , 2020-2030,($THOUSAND)
TABLE 5. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET ANEUPLOIDY BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 6. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR X-LINKED DISEASES, BY REGION , 2020-2030,($THOUSAND)
TABLE 7. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET X-LINKED DISEASES BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 8. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR SINGLE GENE DISORDERS, BY REGION , 2020-2030,($THOUSAND)
TABLE 9. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SINGLE GENE DISORDERS BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 10. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR HLA TYPING, BY REGION , 2020-2030,($THOUSAND)
TABLE 11. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET HLA TYPING BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 12. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR GENDER SELECTION, BY REGION , 2020-2030,($THOUSAND)
TABLE 13. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET GENDER SELECTION BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 14. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($THOUSAND)
TABLE 15. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET OTHERS BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 16. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION, 2020-2030,($THOUSAND)
TABLE 17. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 18. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 19. CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 20. JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 21. INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 22. SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 23. REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 24. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 25. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 26. LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 27. MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 28. AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 29. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 30. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 31. U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 32. CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 33. MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 34. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 35. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 36. GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 37. FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 38. U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 39. ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 40. REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 41.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 42.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 43.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 44.AGILENT TECHNOLOGIES, INC.: NET SALES,
TABLE 45.AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 46.CEGAT GMBH: COMPANY SNAPSHOT
TABLE 47.CEGAT GMBH: OPERATING SEGMENTS
TABLE 48.CEGAT GMBH: PRODUCT PORTFOLIO
TABLE 49.CEGAT GMBH: NET SALES,
TABLE 50.CEGAT GMBH: KEY STRATERGIES
TABLE 51.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 52.ILLUMINA INC.: OPERATING SEGMENTS
TABLE 53.ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 54.ILLUMINA INC.: NET SALES,
TABLE 55.ILLUMINA INC.: KEY STRATERGIES
TABLE 56.INVITAE CORPORATION: COMPANY SNAPSHOT
TABLE 57.INVITAE CORPORATION: OPERATING SEGMENTS
TABLE 58.INVITAE CORPORATION: PRODUCT PORTFOLIO
TABLE 59.INVITAE CORPORATION: NET SALES,
TABLE 60.INVITAE CORPORATION: KEY STRATERGIES
TABLE 61.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 62.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
TABLE 63.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 64.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES,
TABLE 65.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
TABLE 66.NATERA INC.: COMPANY SNAPSHOT
TABLE 67.NATERA INC.: OPERATING SEGMENTS
TABLE 68.NATERA INC.: PRODUCT PORTFOLIO
TABLE 69.NATERA INC.: NET SALES,
TABLE 70.NATERA INC.: KEY STRATERGIES
TABLE 71.PACGENOMICS: COMPANY SNAPSHOT
TABLE 72.PACGENOMICS: OPERATING SEGMENTS
TABLE 73.PACGENOMICS: PRODUCT PORTFOLIO
TABLE 74.PACGENOMICS: NET SALES,
TABLE 75.PACGENOMICS: KEY STRATERGIES
TABLE 76.PERKINELMER, INC.: COMPANY SNAPSHOT
TABLE 77.PERKINELMER, INC.: OPERATING SEGMENTS
TABLE 78.PERKINELMER, INC.: PRODUCT PORTFOLIO
TABLE 79.PERKINELMER, INC.: NET SALES,
TABLE 80.PERKINELMER, INC.: KEY STRATERGIES
TABLE 81.QUEST DIAGNOSTICS INC.: COMPANY SNAPSHOT
TABLE 82.QUEST DIAGNOSTICS INC.: OPERATING SEGMENTS
TABLE 83.QUEST DIAGNOSTICS INC.: PRODUCT PORTFOLIO
TABLE 84.QUEST DIAGNOSTICS INC.: NET SALES,
TABLE 85.QUEST DIAGNOSTICS INC.: KEY STRATERGIES
TABLE 86.REPRODUCTIVE GENETIC INNOVATIONS (RGI): COMPANY SNAPSHOT
TABLE 87.REPRODUCTIVE GENETIC INNOVATIONS (RGI): OPERATING SEGMENTS
TABLE 88.REPRODUCTIVE GENETIC INNOVATIONS (RGI): PRODUCT PORTFOLIO
TABLE 89.REPRODUCTIVE GENETIC INNOVATIONS (RGI): NET SALES,
TABLE 90.REPRODUCTIVE GENETIC INNOVATIONS (RGI): KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(ALD22AU238 )"着床前診断(PGD)のグローバル市場(2020~2030):染色体異常、異数性、X連鎖疾患、単一遺伝子疾患、その他" (英文:Preimplantation Genetics Diagnosis (PGD) Market By Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。